Page 1

20

th

ANNIVERSARY

1998-2018

415 Crossways Park Dr., Suite D Woodbury, NY 11797 516.737.1550 www.lustgarten.org

44080_CV.indd 1-3

TWO DECADES OF MILESTONES & MOMENTUM

8/30/18 3:12 PM


Milestones As we reflect on the past 20 years of milestones and build on the momentum we’ve created in advancing the understanding and treatment of pancreatic cancer, we are pleased that we are more than a voice in the national dialogue on pancreatic

Thank you for sharing this journey with us over these past two decades and for your continued support as we start our next chapter. We could not accomplish all that we do without you.

cancer research; we started the conversation. As the nation’s largest private funder of pancreatic cancer research, we have the profound responsibility of shining a spotlight on pancreatic cancer and doing everything possible to improve the treatment of the disease. To that end, we have directed $165 million to research to date, and we are the only pancreatic cancer research organization that directs 100% of every donation to research.

44080_CV.indd 4-6

9/5/18 1:32 PM


& Momentum In honor of the patients and their loved ones facing this life-threatening disease with tenacity and grace, the researchers in laboratories across the country, the clinicians on the front lines of treatment, and the donors, sponsors, volunteers and other supporters who wholeheartedly believe in our mission, we commemorate this 20th anniversary by looking back at our collective journey and rededicating ourselves to what matters most: improving patient outcomes.

44080_PR.indd 1

8/30/18 2:43 PM


OUR FOCUSED MISSION

Our mission is to advance the scientific and medical research related to the diagnosis, treatment, cure and prevention of pancreatic cancer by: I ncreasing funding and support of research into the biological mechanisms and clinical strategies related to diagnosis, treatment and prevention  acilitating and enhancing the dialogue among members of the medical F and scientific communities about basic and clinical research efforts Heightening public awareness of pancreatic cancer diagnosis, treatment and prevention and providing informational support for patients, their families and friends

44080_PR.indd 2

9/5/18 1:42 PM


CONTENTS Two Decades of Milestones & Momentum

The Need for A Pancreatic Cancer Research Foundation

4–5

Cablevision’s Support

6–7

Research Strategy

8–15

Research Milestones

16–19

Patient Support

20–21

Community Outreach

22–24

Financial Highlights

25

Looking Ahead

26–27

Leadership

28

p.

44080_PR.indd 3

3

9/5/18 1:42 PM


Charles F. Dolan, James L. Dolan, and Marc Lustgarten gather in front of Radio City Music Hall, where the re-opening gala marked the national launch of the Lustgarten Foundation in 1999.

Photo credit: Brian Stanton

The Need for a Pancreatic Cancer Research Foundation In 1998, 51-year-old Marc Lustgarten, Vice Chairman of Cablevision and Chairman of The Madison Square Garden Company, was diagnosed with pancreatic cancer. It quickly became evident that there were few therapy options, and research was practically non-existent. Pancreatic cancer was truly an orphan disease. There was only $16.2 million, or less than one half of one percent of the National Cancer Institute’s (NCI) multibillion dollar budget, allocated to researchers studying pancreatic cancer. Yet, this disease was the nation’s fourth leading cause of cancer deaths. Charles F. Dolan, Chairman of Cablevision, Marc Lustgarten, and Dr. Robert F. Vizza, former President & CEO of St. Francis Hospital, met to explore options to help Marc and all patients impacted with this challenging disease. After discerning the limited availability of effective treatment options and the minimal amount of research being conducted for this disease, they, along with James Dolan, President & CEO of

p.

4

44080_PR.indd 4

Milestones & Momentum

9/5/18 1:42 PM


my husband Marc was first “ When diagnosed, we were completely appalled by the lack of viable treatment options. With the establishment of the Lustgarten Foundation, patients no longer have to feel like they are alone. They have an entire community of researchers, other patients, survivors, and loved ones who are working tirelessly to bring this disease to an end. Marc would be honored to have been the inspiration for such an important organization. Marcia Lustgarten

Marc Lustgarten

Marc Lustgarten’s widow

Cablevision, developed a vision for a foundation dedicated to “advancing the scientific and medical research related to the diagnosis, treatment, cure and prevention of pancreatic cancer.” Initial funding was generously provided by Charles F. Dolan, and Dr. Vizza became President & CEO of the Lustgarten Foundation for Pancreatic Cancer Research. To organize the Foundation, a Board of Directors, Scientific Advisory Board, and Corporate Advisory Board were established. Charles F. Dolan assumed the role of Chairman of the Board, a position which he held for almost 20 years, and he is now Chairman Emeritus. A world-renowned Scientific Advisory Board, comprised of researchers and clinicians from leading institutions across the country, was created to guide our research funding strategy and activities. The Corporate Advisory Board, led by Honorary Chairman former President Jimmy Carter and joined by prominent cable and media executives, enabled the Foundation to promote its mission to millions of Americans.

p.

44080_PR.indd 5

5

8/30/18 2:43 PM


Lustgarten Foundation has played a key role “The in preventing pancreatic cancer from becoming a largely ignored disease. The progress the Lustgarten Foundation has made in tackling this disease from all angles and investing in the most cutting-edge research is having an enormous benefit for patients and their loved ones. Former President Jimmy Carter

Former President Jimmy Carter

Honorary Chairman, Lustgarten Foundation Corporate Advisory Board

Cablevision’s Support Marc’s diagnosis and passing had a significant impact on everyone at Cablevision, which has been a strong supporter of the Foundation from the start. In fact, on October 4, 1999, Cablevision dedicated the Radio City Music Hall re-opening gala to mark the national launch of the Lustgarten Foundation. During the event, the Foundation’s Corporate Advisory Board announced its commitment to air public service announcements (PSAs) designed to heighten awareness for the need for increased research, with the initial PSA featuring former President Jimmy Carter. Then, in 2008, Cablevision made a multi-year commitment to pay all the Lustgarten Foundation’s administrative expenses. This unique partnership ensured that 100% of every dollar donated went directly to pancreatic cancer research. Cablevision also used its unique portfolio of high-profile media and entertainment assets to create disease awareness by joining with the Lustgarten Foundation to launch curePC, a public awareness campaign. President Carter was the first of many notable figures, including Danny Aiello, Joan Cusack, Michael Ealy, Dr. Sanjay Gupta, Felicity Huffman, Larry King, Matthew Modine, Rosie O’Donnell, Dr. Mehmet Oz and Dr. Randy Pausch, to record PSAs for the Foundation. The PSAs, along with media coverage of the curePC campaign activities, reached millions of people and increased awareness for the Foundation and for the need for increased pancreatic cancer research.

p.

6

44080_PR.indd 6

Milestones & Momentum

8/30/18 2:43 PM


.

Photo credit: George Kalinsky for Madison Square Garden

Howard Stringer, Gerald Levin, Barry Diller, James Dolan, Charles Dolan and Robert Wright attend the Radio City Music Hall re-opening gala to mark the national launch of the Lustgarten Foundation.

In 2008, Cablevision Systems Corporation announced their commitment to underwrite all of the Lustgarten Foundation’s administrative expenses ensuring that 100% of every donation will go directly to pancreatic cancer research.

p.

44080_PR.indd 7

7

9/5/18 1:42 PM


has a disease needed more awareness and funding than “ Never pancreatic cancer. In honor of Marc, and to support the thousands of patients and their families who deserve more effective treatment options, we started the Lustgarten Foundation. The Foundation’s research is leading the way toward a cure, and we are proud to have played a role in making that possible. Charles F. Dolan

Chairman Emeritus, Lustgarten Foundation

Research Strategy Working with the National Cancer Institute (NCI) At a meeting with the Executive Director of the NCI in 1998, it was agreed that a program was needed to address the survival rate for pancreatic cancer. In 2000, the Foundation joined with the NCI to participate in the first ever NCI Pancreatic Cancer Progress Review Group (PRG) to develop a national agenda for pancreatic cancer research. Based on recommendations from the PRG, the NCI developed an action plan to increase support and funding for pancreatic cancer research. As part of this plan, the NCI committed to fund at least three Pancreatic Cancer Specialized Programs of Research Excellence (SPOREs) for five years, and the first three SPORE grants were awarded in 2003. This more than doubled the annual commitment of the NCI to pancreatic cancer research. Over time, the Foundation’s support of pancreatic cancer research helped stimulate the NCI to increase its pancreatic cancer research funding to more than $152 million in 2016 and inspired the creation of other pancreatic cancer organizations.

p.

8

44080_PR.indd 8

Milestones & Momentum

9/5/18 1:42 PM


Photo credit: Ben Asen

Dr. Robert F. Vizza speaks at a Lustgarten Foundation scientific conference.

Photo credit: Arthur Fredericks

Members of the scientific community gather to collaborate and share information at a Lustgarten Foundation scientific conference.

The Foundation’s initial research strategy was aimed at attracting researchers to the field of pancreatic cancer. To accomplish this, we sought out and funded researchers from around the world, many of whom have now made it their life’s work to better understand and treat this disease. We awarded a series of $100,000 grants and held scientific conferences bringing together pancreatic cancer leaders to exchange ideas. The Lustgarten Foundation became the driving force in changing the pancreatic cancer research landscape. We then developed a focused research strategy to identify critical areas of research that when successfully completed, will bring us more quickly to a cure. As part of this strategy, the Foundation invites leading scientists to design research proposals that address early detection, new drug development and clinical trials. The competitive grants are reviewed by our SAB and then the best proposals receive funding.

p.

44080_PR.indd 9

9

9/5/18 1:42 PM


PANCREATIC CANCER RESEARCH MAP

UN DE R STA N D ING T H E D ISEA SE

BIOLOGY

D I AG N OS I S

EARLY DETECTION

HEREDITARY FACTORS IMAGING/ SCANS

Creating a Research Map As part of this focused research approach, we implemented a pancreatic cancer research map to strategically move key research initiatives forward. The research map represents a dynamic plan, which adapts as new areas of research are identified. Areas of focus, which continue to guide our research today, include earlier diagnosis and more effective treatment, with the goal of finding a cure.

p.

10

44080_PR.indd 10

Milestones & Momentum

8/30/18 2:43 PM


This research map represents a dynamic plan, which adapts as new areas of focus and research are identified.

CURE

T R E AT M E N T

DRUG DEVELOPMENT

GENETIC RESEARCH METABOLISM STUDIES

IMMUNOTHERAPY DRUG DELIVERY

CLINICAL TRIALS

p.

44080_PR.indd 11

11

8/30/18 2:43 PM


The first Pancreatic Cancer Research Laboratory was established in 2012 at the world renowned Cold Spring Harbor Laboratory.

Photo credit: Diana Davis Creative

Establishing Dedicated Pancreatic Cancer Research Laboratories Once the research groundwork had been laid, we could now expand our efforts to start a world-class pancreatic cancer research laboratory at the Cold Spring Harbor Laboratory on Long Island. Founded in 1890 and home to eight Nobel Prize winners, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and was the ideal location to establish the first Lustgarten Foundation Dedicated Pancreatic Cancer Research Laboratory in 2012. David Tuveson, M.D., Ph.D., a renowned pancreatic cancer expert, was brought on as the director. As a physician-scientist, Dr. Tuveson merges his laboratory and clinical research, enabling him to bring new options to patients more rapidly. Twenty-five scientists in the lab focus exclusively on pancreatic cancer, designing new models of the disease and discovering novel therapeutic and diagnostic platforms. To help meet the need for additional research, we are opening three more dedicated pancreatic cancer research laboratories, one with a clinical focus headed by Brian Wolpin, M.D., MPH, Dana-Farber Cancer Institute, one with a concentration on early detection and therapeutics led by Bert Vogelstein, M.D., Johns Hopkins and one with an expertise in technology and engineering led by Tyler Jacks, Ph.D., Massachusetts Institute of Technology.

p.

12

44080_PR.indd 12

Milestones & Momentum

8/30/18 2:43 PM


Chief Scientist Dr. David Tuveson and members of the Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor Laboratory are making progress in how the disease is understood and treated. Photo credit: Diana Davis Creative

Establishing the Distinguished Scholar, Research Investigator, and Translational Clinical Grant Programs We launched three programs to stimulate new research. The Distinguished Scholar program supports scientists who are at the top in their field and are at the forefront of today’s most exciting breakthroughs in pancreatic cancer research. The Research Investigator program funds talented scientists with historical accomplishments in cancer research. Through these grants, the Foundation attracted prominent scientists from other fields to study pancreatic cancer. We also started the Translational Clinical grant program, which focuses on research “from the bench to the bedside” and funds new, innovative multi-institutional translational research projects.

p.

44080_PR.indd 13

13

9/5/18 1:42 PM


Dr. David Tuveson, Chief Scientist, Lustgarten Foundation; Kerri Kaplan, President & CEO, Lustgarten Foundation; Sung Poblete, Ph.D., R.N., President & CEO, Stand Up To Cancer; and Dr. Phillip A. Sharp, Stand Up To Cancer Scientific Advisory Committee Chair

Collaborating with Stand Up To Cancer The Lustgarten Foundation – Stand Up To Cancer (SU2C) collaboration has played a critical role in promoting therapeutic discoveries that can lead to new treatments. This collaboration, started in 2012, has flourished with currently more than $85 million of combined funding. More than 200 investigators across more than 30 leading research centers in both the United States and the United Kingdom are conducting multicenter, multidisciplinary projects with explicit objectives to drive innovation to the clinic and tackle pancreatic cancer. Together, these collaborative teams have planned, started or completed 23 clinical trials. Additionally, more trials are continuing to open. Our first joint research project focused on Abraxane, which the FDA approved in 2012 in combination with gemcitabine as first line treatment for patients with advanced metastatic pancreatic cancer. This was the first new treatment approved in nine years and is now the standard of care for many patients.

p.

14

44080_PR.indd 14

Milestones & Momentum

9/5/18 1:42 PM


“ This is a watershed moment in the field of

pancreatic cancer research. Through the Collective, these two organizations are uniquely positioned to engage and influence medical institutions, researchers and companies to achieve meaningful results faster.

�

Phillip A. Sharp, Ph.D. Nobel Laureate and Chair of the Stand Up To Cancer Scientific Advisory Committee

In 2018, we joined forces to create the Pancreatic Cancer Collective (pancreaticcancercollective.org) to accelerate the research process and improve patient outcomes. Through the Collective, our two organizations are positioned to attract new collaborators; improve the diagnosis of pancreatic cancer; and support the next generation of pancreatic cancer investigators. The initial funding commitment for the first round of grants is $25 million. Significant funding for additional grants will be ongoing.

p.

44080_PR.indd 15

15

9/5/18 1:42 PM


Photo credit: Cold Spring Harbor Laboratory

has never been a more exciting time in “There pancreatic cancer research. We are now taking our science into the clinic and impacting patient outcomes in real time. I want patients to know that we are making progress.

�

Dr. David Tuveson

Dr. David Tuveson

Chief Scientist, Lustgarten Foundation, Director, Dedicated Research Laboratory at Cold Spring Harbor Laboratory and Director, Cold Spring Harbor Laboratory Cancer Center

Research Milestones Pancreatic cancer research is moving faster than ever before, and there has never been a more exciting or hopeful time for patients. Our Lustgarten-funded researchers have achieved significant milestones in understanding and treating this disease and in detecting the disease earlier—advancements that are already changing patient outcomes.

Mouse Model Created for Pancreatic Cancer and the Role of the Stroma One of the most significant early advancements was achieved by our Chief Scientist, Dr. David Tuveson, during his tenure at the University of Pennsylvania. Dr. Tuveson generated the first genetically engineered mouse model for pancreatic cancer, a model which is now used throughout the scientific community to test new therapies for pancreatic cancer. He also discovered that pancreatic cancer tumors develop a protective membrane, or stroma, which prevents chemotherapy from reaching the cancer cells, impeding treatment.

p.

16

44080_PR.indd 16

Milestones & Momentum

9/5/18 1:42 PM


Pancreatic Cancer Genome Project To further understand the disease so it could be more effectively diagnosed and treated, in 2008, we funded renowned cancer researcher Dr. Bert Vogelstein of Johns Hopkins University’s Kimmel Cancer Center to lead the most comprehensive genetic sequencing that had ever been done for any cancer. The Pancreatic Cancer Genome Project was named one of the top three “Breakthroughs of the Year” by Science. Dr. Vogelstein found that: Pancreatic cancer is caused by a number of mutations acting together, rather than by a single gene. Understanding the mutations offers the potential for new diagnostic tools and therapies. Certain mutated pancreatic cancer genes are cancer-causing, while others are mutations that occur simply as a result of the cancer being formed. The KRAS gene is mutated in nearly 100 percent of all pancreatic cancer tumors. The Pancreatic Cancer Genome Project laid the groundwork for two major milestones to come later: the development of CancerSEEK, a blood screening test, and the use of Keytruda®, an immunotherapy treatment for advanced pancreatic cancer patients whose tumors are mismatch repair deficient.

p.

44080_PR.indd 17

17

8/30/18 2:44 PM


from now, death from “Years cancers will be a lot less common, and that’s going to be in large part due to earlier detection.

Bert Vogelstein, M.D. Director, Lustgarten Foundation Dedicated Laboratory at Johns Hopkins

Bert Vogelstein, M.D.

Early Detection Researchers also led by Dr. Vogelstein designed a blood test called CancerSEEK and published data on this groundbreaking test in 2018. CancerSEEK can detect the presence of early pancreatic cancer and seven other cancers and identify the organ of origin of these cancers. This study lays the groundwork for a single blood screening test for multiple cancers, including pancreatic cancer, that could be offered as part of routine medical checks. The FDA has granted expedited review of the pancreatic and ovarian cancer portion of CancerSEEK. This will accelerate the development process of this important device. The initial research for this blood test began in 2008, when we launched the $1.25 million Pancreatic Cancer Biomarker Development Project, the start of our long-standing Early Detection Initiative, with the goal of developing new earlier detection and screening methods and better imaging techniques.

Immunotherapy In an unprecedented, fast-tracked review, the FDA approved Keytruda® (pembrolizumab) as the first immunotherapy treatment for advanced pancreatic cancer patients whose tumors have a unique genetic mutation called mismatch repair deficiency that alters their capacity to repair DNA, which is a factor in cancer development. It is estimated that approximately 1 in 50 advanced pancreatic cancer patients has a tumor that is mismatch repair deficient. The approval of Keytruda® was named a runner-up for the prestigious “Breakthrough of the Year” award by Science in 2017. p.

18

44080_PR.indd 18

Milestones & Momentum

9/5/18 1:42 PM


The organoid offers the hope of personalized cancer treatments.

Photo credit: Cold Spring Harbor Laboratory

Personalized Medicine and the Organoid Another significant research achievement was Dr. Tuveson’s development of the organoid for pancreatic cancer, which brought the laboratory closer to the clinic. Organoids are three-dimensional cell culture systems which reproduce a patient’s tumor in a dish to test it repeatedly with different drugs, with the aim of identifying new treatments. Presently, it is difficult to determine how a patient will respond to a specific treatment and therefore, patients may be treated with drugs that they won’t respond to. In the laboratory, the organoid becomes the subject for testing. Researchers have demonstrated that organoids can accurately predict how patients with pancreatic cancer will respond to a variety of treatments. This translational technology offers the hope of personalized cancer treatments in the future. In fact, working with Dr. Tuveson, Dr. Brian Wolpin, Dana-Farber Cancer Institute, is now personalizing treatment directly for patients to identify the best secondline treatment options. He is testing each patient’s organoid response to different therapies and genetically sequencing both the tumor DNA and the inherited DNA. The sequencing findings are then used for patients’ treatment, which may include off-label use of medications that treat other cancers. Dr. Wolpin’s recent research findings have suggested that approximately one-third of pancreatic cancer patients may have a genomic alteration that could impact treatment decisions and guide doctors to choose a specific therapy for a personalized medicine approach.

p.

44080_PR.indd 19

19

8/30/18 2:44 PM


Photo credit: Ben Asen

44080_PR.indd 20

8/30/18 2:44 PM


Patient Support As we continue to fund the most innovative research portfolio, we are also focused on serving as a resource for those impacted by pancreatic cancer. The Foundation created and began distributing a variety of free online and printed educational materials to help patients and loved ones make informed healthcare decisions. The Foundation also provides support directly to patients and caregivers who contact our Patient Information Coordinator. Moreover, we collaborate with an online, free clinical trial matching and referral service. In 2016, Let’s Win! Pancreatic Cancer Foundation (letswinpc.org), an interactive online community, was founded as an unprecedented platform that enables doctors, scientists and patients to share fast-breaking information on potentially life-saving pancreatic cancer treatments and clinical trials. The goal is to provide actionable information all in one place. In 2017, to further help patients and their loved ones navigate their pancreatic cancer journey, we launched an online patient/caregiver support community, Pancreatic Cancer Connections (inspire.com), in partnership with Let’s Win! Pancreatic Cancer Foundation and Inspire, a leading healthcare social network.

p.

44080_PR.indd 21

21

9/5/18 1:42 PM


Community Outreach

Recognizing the need to reach out directly to the pancreatic cancer community, we launched the Lustgarten Walk program, starting with one walk in Long Island in 2001, which attracted over 1,200 people and raised more than $140,000. Today, the program has raised more than $40 million, and we hold more than 40 walks annually in nearly 20 states in our quest for a cure. When our walk program started, our participants were walking in memory of loved ones lost to the disease; now, nearly 20 years later, survivors attend our walks and community events, offering inspiration, hope and support to those who are going through the same journey. To complement the walk program, the Foundation’s supporters began holding community events across the country to raise awareness and funding for pancreatic cancer research. Events included golf outings and other sporting activities; weddings, anniversaries, and other milestone celebrations; social activities; and workplace initiatives. Nearly 300 events throughout local communities and large-scale fundraisers are held annually.

p.

22

44080_PR.indd 22

Milestones & Momentum

9/5/18 1:42 PM


Photo credit: Ben Asen

a 20-year period, pancreatic cancer has taken my “Over mother, uncle, sister, and brother from my life. I now know with the inevitability of circumstance that I am ‘wired’ for pancreatic cancer. My wife Shari and I decided to become involved in Lustgarten’s fight, and we hope that organizing this walk will make a difference by raising community awareness and funds for the Lustgarten Foundation.

Neil Piper and Shari Piper Albany, NY Walk Co-Leaders

p.

44080_PR.indd 23

23

8/30/18 2:44 PM


The Rockettes give an exclusive Radio City Christmas Spectacular performance annually at the Holiday Rock & Roll Bash.

Photo credit: Angela Cranford/MSG Photos

The legendary Eagles perform at A Night at The Forum held at the newly renovated Forum in California.

Photo credit: Rebecca Taylor/MSG Photos

For the past 17 years, the annual Holiday Rock & Roll Bash, initiated by Cablevision CEO James Dolan and hosted by Cablevision, The Madison Square Garden Company and AMC Networks, has attracted thousands of attendees and has raised a cumulative total of nearly $24 million for research. In 2013, A Night at The Forum, featuring a private performance by the legendary Eagles, was held to commemorate the re-opening of the newly renovated Forum in California. This sold-out event raised close to $2.5 million for research. Beyond the support we’ve received through our walks and events, we are incredibly grateful for the generosity of our thousands of individual and corporate donors whose outright gifts have been so instrumental to the Foundation’s growth. These gifts, in addition to the substantial financial support provided by Cablevision, have profoundly impacted the amount of research we can fund in areas including earlier detection and new treatments. We recently received significant bequests from the estates of Walter B. Wriston and Mary Brenneisen. We closed out 2017 with a major corporate gift from Creative Bath Products, Inc. in memory of Mathias “Mat” Meinzinger, the company’s founder and former president and CEO. These substantial bequests and gifts are making a difference in the research we can fund that can impact patients and their loved ones.

p.

24

44080_PR.indd 24

Milestones & Momentum

9/5/18 1:42 PM


The Foundation’s annual revenue and funding allocated for research grants have grown significantly, leading to tremendous advancements in pancreatic cancer research.

2000–2017 Annual Revenue (dollars in millions)

$60 50 40 30 20 10 0 ’00

’01

’02

’03

’04

’05

’06

’07

’08

’09

’10

’11

’12

’13

’08

’09

’10

’11

’12

’13

’14

’15

’16

’17

2000–2017 Cumulative Research Grants (dollars in millions)

$200 180 160 140 120 100 80 60 40 20 0 ’00

’01

’02

’03

’04

’05

’06

’07

’14

’15

’16

’17

p.

44080_PR.indd 25

25

9/5/18 1:42 PM


Looking Ahead

p.

26

44080_PR.indd 26

Milestones & Momentum

8/30/18 2:44 PM


As we embrace the future, we are proud to report that we have directed $165 million to research to date, including an unprecedented $40 million in 2017-2018 alone. We are continuing to make large-scale commitments to leading pancreatic cancer researchers, funding studies that seek to stretch the boundaries of science. We have established a private fund for administrative expenses to replace Cablevision’s support, so that we can continue to direct 100% of every donation to pancreatic cancer research. We will continue to focus our research program on the areas that will have the greatest impact for patients: earlier detection and early intervention; personalized medicine; and new therapies. For our earlier detection and early intervention program, we are working to move forward the routine blood test in the doctor’s office, advance imaging capabilities to pick up tumors when they are smaller, and test innovative neoadjuvant therapies so locally advanced pancreatic cancer patients who are now generally not able to have surgery can. We are supporting research that advances personalized medicine by using new technologies to conduct genetic sequencing to identify existing medicines and new therapy combinations that are most likely to improve patient outcomes. We are unwaveringly committed to the guiding principle that it is our duty to change patients’ lives, create a larger community of survivors, and give patients a reason to have an abundance of hope. We believe it’s no longer a matter of “if” we are going to conquer this disease. It’s a matter of when.

p.

44080_PR.indd 27

27

8/30/18 2:44 PM


Board of Directors

Corporate Advisory Board

Scientific Advisory Board

Robert F. Vizza, Ph.D.

The Honorable Jimmy Carter

James Abbruzzese, M.D.

Executive Chairman, Lustgarten Foundation

39th U.S. President, Honorary Chairman

Duke University School of Medicine

Charles F. Dolan

Frank A. Bennack Jr.

Ronald M. Evans, Ph.D.

Executive Vice Chairman and Former Chief Executive Officer, Hearst Corporation

Salk Institute for Biological Studies

Chairman Emeritus, Lustgarten Foundation; Executive Chairman, AMC Networks; Former Chairman, Cablevision Systems Corporation

William Bell Treasurer, Lustgarten Foundation; Former Vice Chairman, Cablevision Systems Corporation

John Cobb Partner, Paul Hastings

Jessica Lustgarten Courtemanche Vice President/Director, Data and Analysis, DigitasLBi

James L. Dolan Executive Chairman, The Madison Square Garden Company; Former Chief Executive Officer, Cablevision Systems Corporation

Jennie Fortunoff Principal, Esterow Events & Consulting, Inc.

Kenneth Goodman, M.D., F.A.C.R. Former Director, Department of Radiology and Attending Physician, St. Francis Hospital

Kerri Kaplan President and Chief Executive Officer, Lustgarten Foundation

Andrew Lustgarten President, The Madison Square Garden Company

Marcia Lustgarten Former Director, Optimum Community, Cablevision Systems Corporation

Sheila Mahony Former Executive Vice President, Communication, Government and Public Affairs, Cablevision Systems Corporation

Barry Diller Chairman and Senior Executive, IAC/InterActiveCorp and Expedia, Inc.

John S. Hendricks Founder and Former Chairman, Discovery Communications

Mel Karmazin Former Chief Executive Officer, Sirius XM Radio, Inc.; Co-Founder, Infinity Broadcasting

Gerald M. Levin Former Chairman and Chief Executive Officer, Time Warner, Inc.

John C. Malone Former President and Chief Executive Officer, Tele-Communications Inc.; Chairman, Liberty Media, Liberty Global and Qurate Retail Group

Rupert Murdoch Executive Chairman, News Corp; Executive Co-Chairman, 21st Century Fox

Sumner M. Redstone Chairman Emeritus, Viacom and CBS Corporation; Chairman, National Amusements

Douglas T. Fearon, M.D. Cold Spring Harbor Laboratory and Weill Cornell Medical College

Charles S. Fuchs, M.D., MPH Yale Cancer Center and Smilow Cancer Hospital

Tyler Jacks, Ph.D. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology

David Paul Kelsen, M.D. Memorial Sloan Kettering Cancer Center

Robert J. Mayer, M.D. Dana-Farber Cancer Institute and Harvard Medical School

Bruce Stillman, Ph.D. Cold Spring Harbor Laboratory

David A. Tuveson, M.D., Ph.D. Lustgarten Foundation Pancreatic Cancer Research Laboratory, Cold Spring Harbor Laboratory

Bert Vogelstein, M.D. The Johns Hopkins University School of Medicine

Brian Wolpin, M.D., MPH Dana-Farber Cancer Institute

Tom Rogers Executive Chairman, WinView

Sir Howard Stringer Non-Executive Director, British Broadcasting Corporation; Retired Chairman of the Board, Sony Corporation

John O’Brien President, O’Brien Partners

Charles R. Schueler Former Executive Vice President, Media and Community Relations, Cablevision Systems Corporation

Willa Shalit Co-Founder and Principal, RTM Limited; Co-Founder, Let’s Win! Pancreatic Cancer Foundation

Adam Silver Commissioner, National Basketball Association

p.

28

44080_PR.indd 28

Milestones & Momentum

8/30/18 2:44 PM

Profile for Lustgarten Foundation

Lustgarten Foundation 20th Anniversary Book  

Lustgarten Foundation 20th Anniversary Book